The White House recently made headlines after the president signed an executive order to speed up research on psychedelics for mental health care. This includes substances like psilocybin and ibogaine.

There were also some big claims made about how effective these treatments might be—especially ibogaine for substance use disorders.

Here’s what’s actually true right now.

---

1. This order is about research—not approval

First, it’s important to understand what this order does and does not do.

What it does:

• Sets aside funding to study psychedelics for mental health conditions
• Speeds up how quickly the FDA reviews research
• Asks for a pathway for limited access under “Right to Try” for certain patients

What it does NOT do:

• It does not make psychedelics legal for general use
• It does not say these treatments are safe or effective

Most psychedelics are still classified as Schedule I drugs. This means they are considered to have no accepted medical use and a high risk of harm. That hasn’t changed.

In simple terms: this order is saying, “Let’s study these faster so we can find out if they work, and act quickly if they do work.”

---

2. The evidence on ibogaine is limited

Ibogaine is a psychedelic substance from a plant found in West Africa. At low doses, it can act like a mild stimulant, and, at higher doses, it can cause hallucinations and altered states of consciousness (like making you feel like you’re in a dream). It impacts many different chemicals throughout the brain.

There’s a lot of interest in using it to treat substance use disorders, especially opioid use disorder. You may hear stories of people feeling “cured” after one dose.

Some public claims have suggested very high success rates, but these are not supported by strong evidence.

Here’s what the research actually shows:

• Even including bad studies, there aren’t many
• Most existing studies are small, short, and at a high risk of bias
• One early report showed ibogaine was associated with reduced withdrawal symptoms and decreased cravings for opioids over the course of 3 days, but this study was really a combination of informal case reports, with no blinding, standardized measures, or control group
• A better-designed study since showed no clear benefit for withdrawal and did not study cravings
• Side effects include nausea, headaches, visual changes, and heart rhythm problems
• There was one fatality in an early study, but it’s unclear it was related to ibogaine

When it comes to research on other potential uses, a study looking at mood changes in healthy people did not find meaningful effects.

So right now, the data on ibogaine is best described as: very limited and unclear.

---

3. Even the best-studied psychedelics have mixed results

Psilocybin is usually regarded as the most studied psychedelic in mental health care.

Some research suggests it may help with depression. But the results are inconsistent:

• Some studies show benefit
• Others show little effect
• Many studies are small or short-term

In some cases, the effects are similar to standard treatments like SSRIs—not clearly better.

So even with the best data we have, the picture is still mixed.

---

4. Psychedelics are hard to study well

There’s another challenge: psychedelics are difficult to study in a rigorous way.

In most clinical trials, researchers try to “blind” participants—meaning people don’t know if they received the treatment or a placebo.

That’s hard to do with psychedelics.

People can usually tell if they are experiencing a psychedelic effect. This can influence results, because expectations alone can change how people feel.

Some studies have shown that both patients and researchers often guess correctly who received the drug. That means some of the benefit seen in studies may come from expectation—not the drug itself.

This doesn’t mean psychedelics don’t work. It just means we have to interpret results carefully.

---

5. Overhyping meds, especially controlled substances, can be extremely harmful

We shouldn’t dismiss psychedelics.

We need better treatments in mental health care—especially for people with severe or long-term conditions. Exploring new options is important.

But we also need to base progress on strong evidence. As with all therapeutic options, we need to know the actual likely benefits and actual likely harms to use them safely and thoughtfully.

Overstating results can:

• Lead to overuse/overprescription
• Lead people to seek unsafe or unproven substances (sometimes illegally)
• Cause individual harm (we don’t fully understand risks yet)
• Cause population level harm, especially if the substances turn out to be habit-forming

We’ve seen this before. The opioid crisis, for example, was partly driven by overconfidence in limited data.

And we are already seeing similar patterns with ketamine. Ketamine is currently being used more broadly than the evidence supports, and rates of ketamine misuse/abuse are climbing.

---

Bottom line

Psychedelics are promising for certain cases—but not proven.

We should:

• Stay curious
• Support high-quality research
• Avoid jumping to conclusions too early
• Avoid overgeneralizing data

Progress in mental health care depends on both innovation and caution. Overhyping treatments can cause real harm.

---

Key Takeaways

FAQs

Are psychedelics approved for mental health treatment?

No. Most psychedelics are still Schedule I and not approved for general medical use.

Does ibogaine cure addiction?

No. Current research does not support cure-level claims.

Is psilocybin effective for depression?

It may help some people, but results are inconsistent and more research is needed.

Why is psychedelic research difficult?

Because participants often know when they are taking a psychedelic, which affects study results.

What’s harmful about overhyping psychedelics?

Overstating or overgeneralizing data on psychedelics is harmful because it can lead people to seek unproven/unsafe treatments, can cause individual physical harm since we are still learning about risks, and cause population level harm, especially if the substances turn out to be habit-forming.

---

References

1. Forsyth B., et al. Effects of low-dose ibogaine on mood and psychological performance. Journal of Ethnopharmacology. 2015;189(2):10–13.
2. Glue P., et al. Single-dose study of noribogaine in people with opioid dependence. Clinical Pharmacology in Drug Development. 2016;5(6):460–468.
3. Mosca A., et al. Ibogaine and noribogaine for substance use disorders: A review of the current research. Current Neuropharmacology. 2023;21(11):2178–2194.
4. Orsini D., et al. Blinding in psychedelic clinical trials: A systematic review. JAMA Psychiatry. 2026 (online ahead of print).